{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:02:07Z","timestamp":1780452127900,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Antiresorptiva geh\u00f6ren weltweit zu den am h\u00e4ufigsten applizierten Arzneimitteln. Ihr Haupteinsatzbereich liegt in der Osteologie und Onkologie. Trotz allgemein guter Vertr\u00e4glichkeit treten bei Patienten unter Therapie unerw\u00fcnschte Arzneimittelwirkungen (UAW) auf. Eine spezifische UAW im Bereich der Kiefer ist die sog. medikamentenassoziierte Osteonekrose (\u201emedication-related osteonecrosis of the jaw\u201c, MRONJ) der Kiefer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Diese Arbeit stellt neuesten Entwicklungen in \u00c4tiologie, Diagnostik und Therapie der MRONJ im Vergleich zu bereits bestehenden Erkenntnissen zusammen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Es wurde eine systematische Literatur\u00fcbersicht der Jahre 2016\u20132021 zu diesem Thema durchgef\u00fchrt. Prospektive Therapiestudien, Diagnostikstudien mit Vergleichsgruppe und innovative Studien zur Pathogenese der MRONJ wurden eingeschlossen und nach den MINORS-Kriterien (\u201emethodological index for non-randomized studies\u201c) bewertet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse und Diskussion<\/jats:title>\n                <jats:p>Die MRONJ tritt bei ca.\u00a02\u201312\u202f% der Patienten, die aus onkologischer Indikation mit Antiresorptiva behandelt werden, auf (osteologische Indikation ca.\u00a00,1\u20131\u202f%). Die Therapie der MRONJ sollte fr\u00fchzeitig und operativ erfolgen. Die Heilungsrate ist bei einem operativen Therapieansatz mit \u00fcber 85\u202f% sehr gut.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00106-021-01130-0","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T13:04:05Z","timestamp":1642683845000},"page":"499-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management von medikamentenassoziierten Kiefernekrosen\u00a0\u2013 Ergebnisse einer Literaturanalyse neuester Studien im Vergleich zu bew\u00e4hrten Strategien","Management of medication-related osteonecrosis of the jaw\u2014a\u00a0review of recent study results in comparison to established strategies"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-4729","authenticated-orcid":false,"given":"Matthias","family":"Tr\u00f6ltzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Tr\u00f6ltzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Pautke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron\u00a0R, Ferrari\u00a0S, Russell\u00a0RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692","journal-title":"Bone"},{"key":"1130_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00106-012-2554-6","volume":"60","author":"F Bast","year":"2012","unstructured":"Bast\u00a0F, Fuss\u00a0H, Schrom\u00a0T (2012) Bilateral bisphosphonate-associated osteonecrosis of the external ear canal : a\u00a0rare case. HNO 60:1127\u20131129","journal-title":"HNO"},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/jbmr.3816","volume":"34","author":"D Bliuc","year":"2019","unstructured":"Bliuc\u00a0D, Tran\u00a0T, van Geel\u00a0T et\u00a0al (2019) Reduced bone loss is associated with reduced mortality risk in subjects exposed to nitrogen bisphosphonates: a mediation analysis. J\u00a0Bone Miner Res 34:2001\u20132011","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1130_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/dj4040045","volume":"4","author":"G Catania","year":"2016","unstructured":"Catania\u00a0G, Monaco\u00a0F, Limberti\u00a0G et\u00a0al (2016) Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures. Dent\u00a0J 4(4):45","journal-title":"Dent J"},{"key":"1130_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.joms.2020.05.037","volume":"78","author":"A Giudice","year":"2020","unstructured":"Giudice\u00a0A, Barone\u00a0S, Diodati\u00a0F et al (2020) Can surgical management improve resolution of medication-related osteonecrosis of the jaw at early stages? A prospective cohort study. J\u00a0Oral Maxillofac Surg 78:1986\u20131999","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.joms.2017.10.024","volume":"76","author":"A Giudice","year":"2018","unstructured":"Giudice\u00a0A, Bennardo\u00a0F, Barone\u00a0S et al (2018) Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study. J\u00a0Oral Maxillofac Surg 76:982\u2013995","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR7","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.oooo.2016.04.007","volume":"122","author":"Y Guo","year":"2016","unstructured":"Guo\u00a0Y, Wang\u00a0D, Wang\u00a0Y et al (2016) Imaging features of medicine-related osteonecrosis of the jaws: comparison between panoramic radiography and computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol 122:e69\u201376","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","volume":"126","author":"F Hallmer","year":"2018","unstructured":"Hallmer\u00a0F, Andersson\u00a0G, G\u00f6trick\u00a0B et al (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw\u2014a 4\u2011year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126:477\u2013485","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1130_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/RLI.0000000000000617","volume":"55","author":"FA Huber","year":"2020","unstructured":"Huber\u00a0FA, Schumann\u00a0P, von Spiczak\u00a0J et al (2020) Medication-related osteonecrosis of the jaw-comparison of bone imaging using ultrashort echo-time magnetic resonance imaging and cone-beam computed tomography. Invest Radiol 55:160\u2013167","journal-title":"Invest Radiol"},{"key":"1130_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00280-021-04262-w","volume":"87","author":"H Ikesue","year":"2021","unstructured":"Ikesue\u00a0H, Doi\u00a0K, Morimoto\u00a0M et al (2021) Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol 87:871\u2013877","journal-title":"Cancer Chemother Pharmacol"},{"key":"1130_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla\u00a0S, Burr\u00a0D, Cauley\u00a0J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a\u00a0task force of the American society for bone and mineral research. J\u00a0Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"1130_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bone.2019.02.007","volume":"122","author":"JW Kim","year":"2019","unstructured":"Kim\u00a0JW, Alfafara\u00a0AMD, Kim\u00a0HY et al (2019) Effects of pH alteration on the pathogenesis of medication-related osteonecrosis of the jaw. Bone 122:45\u201351","journal-title":"Bone"},{"key":"1130_CR13","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.jcms.2016.08.001","volume":"44","author":"C Klingelh\u00f6ffer","year":"2016","unstructured":"Klingelh\u00f6ffer\u00a0C, Zeman\u00a0F, Meier\u00a0J et al (2016) Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J\u00a0Craniomaxillofac Surg 44:1694\u20131699","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx\u00a0RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a\u00a0growing epidemic. J\u00a0Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR15","doi-asserted-by":"publisher","first-page":"3982540","DOI":"10.1155\/2018\/3982540","volume":"2018","author":"R Mauceri","year":"2018","unstructured":"Mauceri\u00a0R, Panzarella\u00a0V, Maniscalco\u00a0L et al (2018) Conservative surgical treatment of bisphosphonate-related osteonecrosis of the jaw with Er,cr:YSGG laser and platelet-rich plasma: a longitudinal study. Biomed Res Int 2018:3982540","journal-title":"Biomed Res Int"},{"key":"1130_CR16","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1007\/s00784-019-02828-w","volume":"23","author":"K Mcgowan","year":"2019","unstructured":"Mcgowan\u00a0K, Ware\u00a0RS, Acton\u00a0C et al (2019) Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study. Clin Oral Invest 23:3967\u20133975","journal-title":"Clin Oral Invest"},{"key":"1130_CR17","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"1130_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.oooo.2021.04.003","volume":"132","author":"H Muraoka","year":"2021","unstructured":"Muraoka\u00a0H, Ito\u00a0K, Hirahara\u00a0N et al (2021) The value of diffusion-weighted imaging in the diagnosis of medication-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 132:339\u2013345","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1130_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis\u00a0O, Kouri\u00a0M, Papadopoulou\u00a0E et al (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a\u00a0systematic review. Support Care Cancer 27:383\u2013394","journal-title":"Support Care Cancer"},{"key":"1130_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/odi.13294","volume":"26","author":"O Nicolatou-Galitis","year":"2020","unstructured":"Nicolatou-Galitis\u00a0O, Papadopoulou\u00a0E, Vardas\u00a0E et al (2020) Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis 26:955\u2013966","journal-title":"Oral Dis"},{"key":"1130_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12149-019-01390-5","volume":"33","author":"I Ogura","year":"2019","unstructured":"Ogura\u00a0I, Kobayashi\u00a0E, Nakahara\u00a0K et al (2019) Quantitative SPECT\/CT imaging for medication-related osteonecrosis of the jaw: a\u00a0preliminary study using volume-based parameters, comparison with chronic osteomyelitis. Ann Nucl Med 33:776\u2013782","journal-title":"Ann Nucl Med"},{"key":"1130_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.crad.2019.05.025","volume":"75","author":"I Ogura","year":"2020","unstructured":"Ogura\u00a0I, Sasaki\u00a0Y, Sue\u00a0M et al (2020) Tc-99m hydroxymethylene diphosphonate SPECT\/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value. Clin Radiol 75:46\u201350","journal-title":"Clin Radiol"},{"issue":"4","key":"1130_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jcms.2010.05.009","volume":"39","author":"S Otto","year":"2011","unstructured":"Otto\u00a0S, Abu-Id\u00a0MH, Fedele\u00a0S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence\u2014a multi-centre study. J\u00a0Craniomaxillofac Surg 39(4):272\u2013277. https:\/\/doi.org\/10.1016\/j.jcms.2010.05.009","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.joms.2009.07.079","volume":"68","author":"S Otto","year":"2010","unstructured":"Otto\u00a0S, Hafner\u00a0S, Mast\u00a0G et al (2010) Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J\u00a0Oral Maxillofac Surg 68:1158\u20131161","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR25","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jcms.2017.07.002","volume":"45","author":"S Otto","year":"2017","unstructured":"Otto\u00a0S, Pautke\u00a0C, Martin Jurado\u00a0O et\u00a0al (2017) Further development of the MRONJ minipig large animal model. J\u00a0Craniomaxillofac Surg 45:1503\u20131514","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto\u00a0S, Pautke\u00a0C, Van den Wyngaert\u00a0T et al (2018) Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 69:177\u2013187","journal-title":"Cancer Treat Rev"},{"key":"1130_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jcms.2016.05.018","volume":"44","author":"S Otto","year":"2016","unstructured":"Otto\u00a0S, Ristow\u00a0O, Pache\u00a0C et al (2016) Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: a prospective cohort study. J\u00a0Craniomaxillofac Surg 44:1073\u20131080","journal-title":"J Craniomaxillofac Surg"},{"issue":"5","key":"1130_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oooo.2020.10.018","volume":"131","author":"S Otto","year":"2021","unstructured":"Otto\u00a0S, Schn\u00f6dt\u00a0EM, Haidari\u00a0S et al (2021) Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study. Oral Surg Oral Med Oral Pathol Oral Radiol 131(5):519\u2013526","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1130_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto\u00a0S, Troltzsch\u00a0M, Jambrovic\u00a0V et\u00a0al (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J\u00a0Craniomaxillofac Surg 43:847\u2013854","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bone.2012.04.020","volume":"51","author":"C Pautke","year":"2012","unstructured":"Pautke\u00a0C, Kreutzer\u00a0K, Weitz\u00a0J et\u00a0al (2012) Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model. Bone 51:592\u2013599","journal-title":"Bone"},{"issue":"3","key":"1130_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.joms.2020.10.005","volume":"79","author":"C Pautke","year":"2021","unstructured":"Pautke\u00a0C, Wick\u00a0A, Otto\u00a0S et al (2021) The type of antiresorptive treatment influences the time to onset and the surgical outcome of medication-related osteonecrosis of the jaw. J\u00a0Oral Maxillofac Surg 79(3):611\u2013621. https:\/\/doi.org\/10.1016\/j.joms.2020.10.005","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR32","doi-asserted-by":"publisher","first-page":"1560175","DOI":"10.1155\/2017\/1560175","volume":"2017","author":"NJ Rao","year":"2017","unstructured":"Rao\u00a0NJ, Wang\u00a0JY, Yu\u00a0RQ et al (2017) Role of periapical diseases in medication-related osteonecrosis of the jaws. Biomed Res Int 2017:1560175","journal-title":"Biomed Res Int"},{"key":"1130_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","volume":"41","author":"IR Reid","year":"2007","unstructured":"Reid\u00a0IR, Bolland\u00a0MJ, Grey\u00a0AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318\u2013320","journal-title":"Bone"},{"key":"1130_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijom.2016.10.008","volume":"46","author":"O Ristow","year":"2017","unstructured":"Ristow\u00a0O, Otto\u00a0S, Gei\u00df\u00a0C et al (2017) Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a\u00a0randomized controlled feasibility study. Int J Oral Maxillofac Surg 46:157\u2013166","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1130_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","volume":"43","author":"O Ristow","year":"2015","unstructured":"Ristow\u00a0O, Otto\u00a0S, Troeltzsch\u00a0M et al (2015) Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J\u00a0Craniomaxillofac Surg 43:290\u2013293","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","volume":"47","author":"O Ristow","year":"2019","unstructured":"Ristow\u00a0O, R\u00fcckschlo\u00df\u00a0T, M\u00fcller\u00a0M et al (2019) Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J\u00a0Craniomaxillofac Surg 47:491\u2013499","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR37","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers\u00a0MJ, M\u00f6nkk\u00f6nen\u00a0J, Munoz\u00a0MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493","journal-title":"Bone"},{"key":"1130_CR38","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero\u00a0SL, Dodson\u00a0TB, Fantasia\u00a0J et al (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J\u00a0Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"1130_CR39","volume-title":"S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)","author":"E Schiegnitz","year":"2018","unstructured":"Schiegnitz\u00a0E, Al-Nawas\u00a0B, Hoefert\u00a0S et al (2018) S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)"},{"key":"1130_CR40","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20210036","author":"P Schumann","year":"2021","unstructured":"Schumann\u00a0P, Morgenroth\u00a0S, Huber\u00a0FA et al (2021) Correlation of dynamic contrast-enhanced bone perfusion with morphologic ultra-short echo time MR imaging in medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol. https:\/\/doi.org\/10.1259\/dmfr.20210036","journal-title":"Dentomaxillofac Radiol"},{"key":"1130_CR41","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/bcp.13759","volume":"85","author":"MK Skj\u00f8dt","year":"2019","unstructured":"Skj\u00f8dt\u00a0MK, Frost\u00a0M, Abrahamsen\u00a0B (2019) Side effects of drugs for osteoporosis and metastatic bone disease. Br J Clin Pharmacol 85:1063\u20131071","journal-title":"Br J Clin Pharmacol"},{"key":"1130_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim\u00a0K, Nini\u00a0E, Forestier\u00a0D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a\u00a0new instrument. ANZ J Surg 73:712\u2013716","journal-title":"ANZ J Surg"},{"key":"1130_CR43","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jcms.2017.05.003","volume":"45","author":"G Topaloglu","year":"2017","unstructured":"Topaloglu\u00a0G, Koseoglu\u00a0OT, Karaca\u00a0C et al (2017) The effect of chronic dental inflammation on development of stage 0 medication-related osteonecrosis of the jaw. J\u00a0Craniomaxillofac Surg 45:1158\u20131164","journal-title":"J Craniomaxillofac Surg"},{"key":"1130_CR44","doi-asserted-by":"publisher","first-page":"20200043","DOI":"10.1259\/dmfr.20200043","volume":"49","author":"H Toshima","year":"2020","unstructured":"Toshima\u00a0H, Ogura\u00a0I (2020) Assessment of inflammatory jaw pathologies using bone SPECT\/CT maximum standardized uptake value. Dentomaxillofac Radiol 49:20200043","journal-title":"Dentomaxillofac Radiol"},{"key":"1130_CR45","first-page":"c85","volume":"78","author":"M Troeltzsch","year":"2012","unstructured":"Troeltzsch\u00a0M, Woodlock\u00a0T, Kriegelstein\u00a0S et\u00a0al (2012) Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J\u00a0Can Dent Assoc 78:c85","journal-title":"J Can Dent Assoc"},{"key":"1130_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00774-020-01195-x","volume":"39","author":"N Ueda","year":"2021","unstructured":"Ueda\u00a0N, Aoki\u00a0K, Shimotsuji\u00a0H et al (2021) Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer. J\u00a0Bone Miner Metab 39:623\u2013630","journal-title":"J Bone Miner Metab"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-021-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-021-01130-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-021-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T14:04:52Z","timestamp":1656511492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-021-01130-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1007\/s00106-021-01130-0","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"31 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Tr\u00f6ltzsch, M.\u00a0Tr\u00f6ltzsch, C.\u00a0Pautke und S.\u00a0Otto geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}